Christopher F. Nicodemus, MD FACP, is Founder, President and Chief Scientific Officer of AIT Strategies. He served as Chairman and Chief Scientific Officer of Advanced Immune Therapeutics, Inc., from 2008-2012. Dr. Nicodemus received undergraduate training at Harvard College and received his MD degree Upstate Medical University in Syracuse, NY. He trained in Internal Medicine and completed a Research and Clinical fellowship in the laboratory of K Frank Austen, Department of Rheumatology and Clinical Immunology at Brigham and Women’s Hospital, Harvard Medical School, Boston. He held various research and clinical appointments at Harvard while pursuing a career in biotechnology. He has held executive positions at Pfizer, ImmuLogic, Diatide, AltaRex, United Therapeutics and Advanced Immune Therapeutics, Inc. He is a member of Alpha Omega Alpha and a fellow of the American College of Physicians.
His career has been dedicated to research into immune modulation and experimental medicine with a focus on the application of cellular and molecular biology to clinical immunology and drug development. Early efforts using peptides as immunogens, led to the study of T-cell reactive epitopes and tolerance induction, which subsequently evolved into study of antibodies to elicit immunity. An early clinical focus in allergy, autoimmunity, and asthma has more recently shifted to a focus on tumor immunology, with an emphasis on ovarian cancer immunobiology and immunotherapy. Dr. Nicodemus has conceived, designed and executed and published numerous clinical studies, holds multiple patents, and has extensive regulatory experience with the successful completion of three New Drug Applications. Dr. Nicodemus actively publishes and lectures in the field of translational immunology and Immuno-Oncology.
The therapeutic IgE technology developed in the laboratories of Advanced Immune Therapeutics, Inc. has been acquired by Quest PharmaTech of Edmonton Alberta. AIT Strategies is an active participant and collaborator in the continuing development of both IgG and IgE technologies at the OncoQuest subsidiary and with global collaborators interested in indirect immunization as a preferred approach to initiating anti-tumor immunity with therapeutic intent. The challenge for the scientific community is now to extend the initial success seen in some cancer patients treated with immune check point inhibitors to a broader patient population. Dr. Nicodemus has been advocating selective and scheduled combinatorial therapy with indirect immunization administered to leverage windows of diminished immune suppression that occur transiently in association with select standard cancer therapies. Dr. Nicodemus remains open to additional collaborations to further explore the potential of novel combinations
2021 AIT Strategies